<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05794425</url>
  </required_header>
  <id_info>
    <org_study_id>UCB&amp;MSCs-BMF-2023</org_study_id>
    <nct_id>NCT05794425</nct_id>
  </id_info>
  <brief_title>Clinical Study of UCB Combined With UC-MSCs in the Treatment of Bone Marrow Failure Disorders</brief_title>
  <official_title>A Multicenter Collaborative Clinical Study of Umbilical Cord Blood Combined With Umbilical Cord Derived Mesenchymal Stem Cells in the Treatment of Bone Marrow Failure Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Qilu Stem Cells Engineering Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shandong Third Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dezhou People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Children's Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Shandong First Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tai'an Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Linyi People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Linyi Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rizhao People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lanling People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Jining No.1 People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The affiliated hospital of Jining medical college</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zibo municipal hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Binzhou People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Binzhou Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shengli Oilfield Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weihai Municipal Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weihai Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Shandong University of traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gansu Provincial Hospital of Traditional Chinese Medicine (TCM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuwei People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gansu Wuwei Tumour Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yuncheng Institute of Hematology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaifeng Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhengzhou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Air Force Hospital of Western War Zone</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First People' s Hospital of Yunnan Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zigong No.1 Peoples Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First People's Hospital of Jingzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangxi Province Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shandong Qilu Stem Cells Engineering Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The multicenter collaborative clinical study conducted a systematic clinical observation in&#xD;
      the treatment of bone marrow failure diseases via UCB&amp;UC-MSCs , in order to observe its&#xD;
      clinical efficacy and safety.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2023</start_date>
  <completion_date type="Anticipated">April 2026</completion_date>
  <primary_completion_date type="Anticipated">April 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To evaluate efficacy of UCB in combination with UC-MSCs in the treatment of bone marrow failure disorders</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To assess Progression-free Survival (PFS) of the combination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To assess overall survival (OS) of the combination</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Bone Marrow Failure Disorders</condition>
  <arm_group>
    <arm_group_label>Cyclosporine A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>UCB+UC-MSCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine A</intervention_name>
    <description>3-5 mg per kilogram per day.</description>
    <arm_group_label>Cyclosporine A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Umbilical cord blood &amp; Umbilical cord derived mesenchymal stem cells</intervention_name>
    <description>Intravenous infusion of umbilical cord blood and umbilical cord derived mesenchymal stem cells (5-8×10^7) at 1 week interval.</description>
    <arm_group_label>UCB+UC-MSCs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with bone marrow failure disorders, including aplastic anemia, pure red cell&#xD;
             aplastic anemia, immune-related pancytopenia, paroxysmal nocturnal hemoglobinuria,&#xD;
             myelodysplastic syndrome, acute arrest of hemopoiesis, and cytopenia of unknown&#xD;
             significance;&#xD;
&#xD;
          2. Patients with no severe impairment of liver and kidney function (total bilirubin&#xD;
             (TBIL): ≤ 1.5×ULN; ALT or AST: ≤ 2.5×ULN; Alkaline phosphatase: ≤ 3×ULN; Serum&#xD;
             creatinine: ≤ 1.5×ULN);&#xD;
&#xD;
          3. The prothrombin time (PT) or activated partial thrombin time (APTT) or international&#xD;
             normalized ratio (INR): ≤ 1.5×ULN in the absence of anticoagulant therapy;&#xD;
&#xD;
          4. The left ventricular ejection fraction (LVEF): ≥50% by cardiac echocardiography&#xD;
&#xD;
          5. Hepatitis B surface antigen (HBsAg) and Hepatitis B core antibody (HBcAb) were&#xD;
             negative. If any of the above items is positive, the HBV DNA titer in peripheral blood&#xD;
             must be lower than the detection limit or 1×10^3 copys/ml;&#xD;
&#xD;
          6. Patients with no plans for stem cell transplantation;&#xD;
&#xD;
          7. Patients with ECOG 0-2;&#xD;
&#xD;
          8. Those who voluntarily participate in this clinical study and have signed an informed&#xD;
             consent .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have suffered malignant tumors other than squamous cell carcinoma of the&#xD;
             skin, basal cell carcinoma of the skin, malignant melanoma cured by surgery, and&#xD;
             carcinoma in situ of the cervix in the past 5 years;&#xD;
&#xD;
          2. Patient with severe cardiac insufficiency (e.g. grade Ⅲ、Ⅳ by NYHA classification&#xD;
             NYHA), and medically uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or&#xD;
             diastolic blood pressure ≥110 mmHg);&#xD;
&#xD;
          3. Patients with severe mental illness;&#xD;
&#xD;
          4. Patients with clinically significant infection should be recruited with delay;&#xD;
&#xD;
          5. AST or ALT: above 3 times the upper limit of normal, creatinine, total bilirubin, or&#xD;
             alkaline: phosphatase (ALP): above 1.5 times the upper limit of normal;&#xD;
&#xD;
          6. Patients with test positive for HIV, HCV or syphilis;&#xD;
&#xD;
          7. Patients with severe allergies or allergic to the active ingredients, excipients of&#xD;
             the drug, or blood products in this clinical trials;&#xD;
&#xD;
          8. Patients who are pregnant or breastfeeding, or have a childbirth plan in the near&#xD;
             future;&#xD;
&#xD;
          9. Patients receive allogeneic/autologous hematopoietic stem cell transplantation by the&#xD;
             assessment of investigators;&#xD;
&#xD;
         10. There are other conditions that the investigators consider inappropriate for&#xD;
             inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zhe Yu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong Provincial Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>zhe Yu, MD</last_name>
    <phone>86-18753103739</phone>
    <email>doctoryu1120@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shandong Provincial Third Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250031</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>zhe Yu, MD</last_name>
      <phone>86-18753103739</phone>
      <email>doctoryu1120@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 20, 2023</study_first_submitted>
  <study_first_submitted_qc>March 20, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>March 20, 2023</last_update_submitted>
  <last_update_submitted_qc>March 20, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Marrow Failure Disorders</mesh_term>
    <mesh_term>Pancytopenia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

